ProCE Banner Activity

Phase IIb Trial of LSD1 Inhibitor Bomedemstat in Patients With Essential Thrombocythemia Resistant or Intolerant to Standard Therapy

Conference Coverage

In this phase IIb study, the LSD1 inhibitor bomedemstat showed clinically meaningful platelet reduction in patients with essential thrombocythemia and inadequate response or intolerance to standard-of-care treatment.

Released: December 13, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.